Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Change in Accured Expenses (2023 - 2025)

Immunome (IMNM) has disclosed Change in Accured Expenses for 3 consecutive years, with $5.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 13155.81% year-over-year to $5.7 million, compared with a TTM value of $4.5 million through Dec 2025, down 66.55%, and an annual FY2025 reading of $4.5 million, down 66.55% over the prior year.
  • Change in Accured Expenses was $5.7 million for Q4 2025 at Immunome, down from $6.7 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $6.9 million in Q2 2024 and bottomed at -$8.5 million in Q1 2025.
  • Average Change in Accured Expenses over 3 years is $1.6 million, with a median of $1.0 million recorded in 2023.
  • Peak annual rise in Change in Accured Expenses hit 13155.81% in 2025, while the deepest fall reached 1373.69% in 2025.
  • Year by year, Change in Accured Expenses stood at $2.1 million in 2023, then plummeted by 97.92% to $43000.0 in 2024, then skyrocketed by 13155.81% to $5.7 million in 2025.
  • Business Quant data shows Change in Accured Expenses for IMNM at $5.7 million in Q4 2025, $6.7 million in Q3 2025, and $619000.0 in Q2 2025.